Tuesday, March 11, 2014 4:49:04 PM
ImmuCell Announces Increase in Product Sales and Other Annual Financial Results
.
Marketwired
ImmuCell Corporation
February 13, 2014 8:00 AM
.
.
..
.
.
PORTLAND, ME--(Marketwired - Feb 13, 2014) - ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and twelve-month periods ended December 31, 2013.
During the three-month period ended December 31, 2013, product sales increased by 9.7%, or $138,000, to $1,559,000 in comparison to $1,421,000 during the same period in 2012. During the twelve-month period ended December 31, 2013, product sales increased by 11.5%, or $617,000, to $6,007,000 in comparison to $5,390,000 during the same period in 2012.
"We have now increased product sales during the last six consecutive quarters and for twelve of the last thirteen quarters. Sales of First Defense® and related product line extensions increased by 16.5% during the fourth quarter and 14.4% during the year ended December 31, 2013," commented Michael F. Brigham, President and CEO.
The net operating (loss) was ($210,000) during the three-month period ended December 31, 2013, in contrast to a net operating income of $12,000 during the same period in 2012. The net (loss) was ($151,000), or ($0.05) per share, during the three-month period ended December 31, 2013, in comparison to a net (loss) of ($17,000), or ($0.01) per share, during the same period in 2012.
Net operating (loss) was ($20,000) during the twelve-month period ended December 31, 2013, in contrast to net operating income of $245,000 during the same period in 2012. Net income was $117,000, or $0.04 per share, during the twelve-month period ended December 31, 2013, in comparison to net income of $90,000, or $0.03 per share, during the same period in 2012.
Regarding the fourth quarter loss, Mr. Brigham added, "During the fourth quarter, we incurred approximately $110,000 in expenses as we initiated our planned investment in a Nisin production plant for Mast Out®. Further, we reduced production output during the last six months of 2013 in order to replace and repair certain pieces of critical process equipment, which resulted in an increase in cost of goods sold. We expect our gross margin percentage to be more in line with our historical norms during 2014."
Cash, cash equivalents and short-term investments increased by 7%, or $342,000, to $5,255,000 as of December 31, 2013, in comparison to $4,914,000 as of December 31, 2012. Stockholders' equity increased by 2%, or $201,000, to $9,396,000 as of December 31, 2013, in comparison to $9,195,000 as of December 31, 2012. The Company had 3,026,000 shares of common stock outstanding as of December 31, 2013.
(Unaudited)
For the Three-Month Periods Ended December 31, For the Twelve-Month Periods Ended December 31,
(In thousands, except per share amounts) 2013 2012 2013 2012
Product sales $ 1,559 $ 1,421 $ 6,007 $ 5,390
Costs of goods sold 951 671 2,947 2,336
Gross margin 608 750 3,060 3,054
Product development expenses 325 234 1,154 918
Selling and administrative expenses 493 503 1,926 1,891
Operating expenses 818 737 3,080 2,809
NET OPERATING (LOSS) INCOME (210 ) 13 (20 ) 245
Other (expenses) revenues, net (43 ) (24 ) 225 (53 )
(LOSS) INCOME BEFORE INCOME TAXES (253 ) (11 ) 205 192
Income tax (benefit) expense (102 ) 6 88 102
NET (LOSS) INCOME $ (151 ) $ (17 ) $ 117 $ 90
Weighted average common shares outstanding:
Basic 3,021 3,019 3,019 3,018
Diluted 3,021 3,019 3,085 3,108
NET (LOSS) INCOME PER SHARE:
Basic $ (0.05 ) $ (0.01 ) $ 0.04 $ 0.03
Diluted $ (0.05 ) $ (0.01 ) $ 0.04 $ 0.03
(In thousands) As of December 31, 2013 As of December 31, 2012
Cash, cash equivalents and short-term investments $ 5,255 $ 4,914
Total assets 10,961 11,030
Net working capital 6,632 6,697
Stockholders' equity $ 9,396 $ 9,195
About ImmuCell: ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, (http://www.immucell.com).
Contact:
Michael F. Brigham
President and CEO
(207) 878-2770 Ext. 3106
Recent ICCC News
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 • GlobeNewswire Inc. • 04/09/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 06:55:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:05:32 PM
- ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023 • GlobeNewswire Inc. • 02/27/2024 09:05:00 PM
- ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023 • GlobeNewswire Inc. • 02/16/2024 02:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:05:32 PM
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023 • GlobeNewswire Inc. • 01/08/2024 09:05:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 08:22:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:05:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:05:46 PM
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023 • GlobeNewswire Inc. • 11/13/2023 09:05:00 PM
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023 • GlobeNewswire Inc. • 11/07/2023 05:15:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 08:05:21 PM
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023 • GlobeNewswire Inc. • 10/05/2023 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2023 04:25:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2023 06:49:33 PM
- ImmuCell Announces Submission of CMC Technical Section to the FDA • GlobeNewswire Inc. • 08/29/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:05:44 PM
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023 • GlobeNewswire Inc. • 08/10/2023 08:05:00 PM
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023 • GlobeNewswire Inc. • 08/07/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/21/2023 01:04:28 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/13/2023 06:28:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2023 08:05:21 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM